Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Pender · SciRah

Researcher profile · Semantic Scholar

A. Pender

Share profile

A. Pender — researcher profile on SciRah

h-index: 10
Works: 47
Citations: 419

Most-cited papers

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
A. Pender, E. Titmuss, E. Pleasance, K. Fan +21 more
2020Clinical Cancer Research73 citations
Semantic Scholar
International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.
A. Whale, Alison S. Devonshire, G. Karlin-Neumann, John F. Regan +30 more
2017Analytical Chemistry67 citations Open access
Semantic Scholar
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach
A. Pender, I. Garcia-Murillas, S. Rana, R. Cutts +9 more
2015PLoS ONE62 citations Open access
Semantic Scholar
Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
A. Shokoohi, Z. Al-Hashami, S. Moore, A. Pender +5 more
2021Cancer Medicine27 citations Open access
Semantic Scholar
Optimising Cancer Vaccine Design in Sarcoma
A. Pender, Robin L. Jones, S. Pollack
2018Cancers25 citations Open access
Semantic Scholar
Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation
R. Fisher, A. Pender, K. Thillai, S. Chowdhury +4 more
2012Frontiers in Oncology25 citations Open access
Semantic Scholar
Intratumoral heterogeneity in programmed death‐ligand 1 immunoreactivity is associated with variation in non‐small cell lung carcinoma histotype
Julia R. Naso, Gang-ping Wang, A. Pender, S. Wong +4 more
2020Histopathology21 citations
Semantic Scholar
Lung Cancer in Canada.
C. Ho, S. Lefresne, M. Liberman, A. Mcguire +5 more
2019Journal of Thoracic Oncology20 citations Open access
Semantic Scholar
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
A. Pender, Elizabeth J. Davis, D. Chauhan, C. Messiou +10 more
2018Medical Oncology17 citations Open access
Semantic Scholar
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
A. Pender, Robin L. Jones
2017Clinical Pharmacology : Advances and Applications11 citations Open access
Semantic Scholar
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
Rebekah Rittberg, B. Leung, A. Shokoohi, A. Pender +4 more
2023Current Oncology10 citations Open access
Semantic Scholar
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood
Natalie M. Edner, E. Ntavli, L. Petersone, Chun-Jing Wang +12 more
2023Immunotherapy Advances9 citations Open access
Semantic Scholar
Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.
R. Fisher, A. Pender, K. Thillai, S. Chowdhury +4 more
2011Journal of Clinical Oncology9 citations
Semantic Scholar
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
Lauren Jones, Rebekah Rittberg, B. Leung, A. Shokoohi +5 more
2022Current Oncology8 citations Open access
Semantic Scholar
EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
A. Pender, Curtis B. Hughesman, Elaine Law, A. Kristanti +9 more
2020Translational Lung Cancer Research8 citations Open access
Semantic Scholar
Olaratumab for the treatment of soft-tissue sarcoma.
A. Pender, Robin L. Jones
2017Future Oncology5 citations
Semantic Scholar
Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
B. Leung, A. Shokoohi, Z. Al-Hashami, S. Moore +5 more
2023BMC Cancer3 citations Open access
Semantic Scholar
The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
A. Pender, S. Popat
2015Therapeutic Advances in Respiratory Disease3 citations
Semantic Scholar
Understanding lung cancer molecular subtypes
A. Pender, S. Popat
20143 citations
Semantic Scholar
EP08.01-074 'Long Responders' Compared to 'Non-Responders' to a First Line Immune Checkpoint Inhibitor in Incurable Non-Small Cell Lung Cancer
R. Rittberg, B. Leung, A. Shokoohi, Z. Al-Hashami +4 more
2022Journal of Thoracic Oncology2 citations Open access
Semantic Scholar
1138P Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 >/= 50%: 3 weekly compared to 6 weekly dosing
L. Jones, R. Rittberg, B. Leung, A. Shokoohi +5 more
2022Annals of Oncology2 citations Open access
Semantic Scholar
Side effects and complications of cancer and its treatment
A. Pender, S. Moorcraft, Daniel L. Y. Lee
20142 citations
Semantic Scholar
Abstract 3851: Ultrasensitive ctDNA monitoring predicts early response of immunotherapy in recurrent metastatic non-small cell lung cancer
Kishen R. Patel, Bailiang Li, C. Abbott, C. Naceur-Lombardelli +19 more
2026Cancer Research1 citations
Semantic Scholar
EP08.02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
L. Jones, R. Rittberg, B. Leung, A. Shokoohi +5 more
2022Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world.
Rebekah Rittberg, Lauren Jones, B. Leung, A. Shokoohi +7 more
2022Journal of Clinical Oncology1 citations
Semantic Scholar
1308P Effect of current treatment evolution in advanced NSCLC on overall survival in the real world
A. Shokoohi, Z. Al-Hashami, S. Moore, A. Pender +5 more
20201 citations Open access
Semantic Scholar
Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.
A. Pender, S. Rana, I. Garcia-Murillas, R. Cutts +6 more
20161 citations
Semantic Scholar
An International Inter-Laboratory Digital PCR Study Demonstrates High Reproducibility for the Measurement of a Rare Sequence Variant
A. Whale, Alison S. Devonshire, G. Karlin-Neumann, John F. Regan +30 more
2016bioRxiv1 citations Open access
Semantic Scholar
3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice
A. Pender, S. Rana, E. Delgado, P. Proszek +8 more
20161 citations
Semantic Scholar
33 Outcomes of patients undergoing adjuvant platinum–vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC)
A. Pender, J. Coward, R. Gunapala, J. Bhosle +2 more
20131 citations
Semantic Scholar
Intrapatient correlation of clinical benefit from VEGF and mTOR inhibition in metastatic renal cell carcinoma.
G. Ratnayake, A. Pender, Lisa M. Pickering, M. Gore +1 more
2011Journal of Clinical Oncology1 citations
Semantic Scholar
Treatment patterns and clinical outcomes in patients with loco-regional recurrent melanoma in the United Kingdom
A. Pender, A. Booth, Noami Berfeld, Harmony Omeife +8 more
2026BMC Cancer0 citations Open access
Semantic Scholar
PL03.04: Zipalertinib Plus Chemotherapy for 1st Line NSCLC with EGFR Exon 20 Insertions: Results From the Phase 3 Trial (REZILIENT 3)
D. Tan, P. Danchaivijitr, Y. Shinno, C. Ho +28 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience
Saira Khalique, J. Lubel, C. Docherty, A. Kanu +6 more
2021Lung Cancer0 citations
Semantic Scholar
Abstract 1647: CAPTIV-8: A prospective trial of atezolizumab using a multivariate model incorporating whole genome and transcriptome analysis
E. Titmuss, A. Pender, E. Pleasance, S. Brown +19 more
2021Immunology0 citations
Semantic Scholar
Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults.
B. Leung, A. Shokoohi, Z. Al-Hashami, S. Moore +5 more
2021Journal of Clinical Oncology0 citations
Semantic Scholar
MA15.06 Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults
B. Leung, C. Ho, J. Wu, Y. Wang +5 more
2021Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Imaging-Guided Palliative Procedures: Tendon and Bursa Injection
A. Chavda, A. Pender, M. Cresswell
20210 citations
Semantic Scholar
Confirmation of germline variants identified by tumor testing: A population-based study.
A. Pender, A. Karsan, S. Yip, I. Bosdet +4 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
A. Pender, Curtis B. Hughesman, Elaine Law, A. Kristanti +8 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Canadian Lung Cancer Conference 2019.
A. Pender, E. Dunne, S. Wong, C. Ho +1 more
2019Current Oncology0 citations Open access
Semantic Scholar
P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease
A. Pender, Curtis B. Hughesman, Elaine Law, A. Kristanti +8 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
A. Pender, E. Titmuss, E. Pleasance, K. Fan +12 more
2019Annals of Oncology0 citations Open access
Semantic Scholar
Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA
A. Pender, I. Garcia-Murillas, S. Rana, D. D. de Castro +3 more
20150 citations
Semantic Scholar
38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience
A. Pender, J. Coward, R. Gunapala, J. Bhosle +2 more
20140 citations
Semantic Scholar
13 Molecular profiling of non-small cell lung cancer (NSCLC) – the liquid biopsy comes of age
A. Pender, I. Garcia-Murillas, D. D. de Castro, S. Popat +1 more
20140 citations
Semantic Scholar
21 Weekly paclitaxel and three weekly docetaxel appear active and well-tolerated in third and fourth-line advanced NSCLC patients
A. Pender, I. Letsa, A. Reid, T. Waddell +10 more
20120 citations
Semantic Scholar
An audit of the management of Staphylococcus aureus bloodstream infections over two years in a District General Hospital in the United Kingdom: Category: Clinical lesson
A. Pender, D. Mack
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Leung×11
Invite
B. Leung — researcher profile on SciRah
S. Popat×10
Invite
S. Popat — researcher profile on SciRah
A. Shokoohi×10
Invite
A. Shokoohi — researcher profile on SciRah
Z. Al-Hashami×10
Invite
Z. Al-Hashami — researcher profile on SciRah

×8

Invite

S. Wong — researcher profile on SciRah

Invite

S. Yip — researcher profile on SciRah

Invite

C. Ho — researcher profile on SciRah

Invite

J. Laskin — researcher profile on SciRah

Invite

S. Wong — researcher profile on SciRah

I. Garcia-Murillas×5

Invite

I. Garcia-Murillas — researcher profile on SciRah

Invite

J. Bhosle — researcher profile on SciRah

Invite

M. O'Brien — researcher profile on SciRah